Potentially Improved Response of COVID-19 vaccinated Nasopharyngeal Cancer Patients to Combination Therapy with Anti-PD-1 Blockade and Chemotherapy
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Anti-PD-1 treatment was demonstrated to be effective in nasopharyngeal cancer (NPC) patients1. During the COVID-19 pandemic, concern was raised whether anti-PD-1 treatment can interfere with COVID-19 vaccination in NPC patients, although our previous study showed that the efficacy and safety of anti-PD-1 treatment was not reduced in general cancer patients vaccinated with SinoVac2. NPC affects the upper respiratory tract, where the COVID-19 infection takes place. Possible interferences between anti-PD-1 treatment and COVID-19 vaccination in NPC patients remain elusive. Our study aims to fill this gap.
Annals of Oncology , éditorial, 2022